TrialDiabetes, obesity & metabolism2013

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.

J-F Yale et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.